January 25, 2017
Eisai says that its cancer drug Lenvima (lenvatinib) hit the primary endpoint in a Phase III study for the treatment of liver cancer, proving non-inferior to Nexavar. That success will set up regulatory filings in the US, Europe and Asia, the company adds. Liver cancer is a particularly big problem in China, where Eisai plans to roll out an application in the near future.
Tokyo-based Eisai tested their drug it in a study with 954 patients and says that this drug scored on the overall survival rate. And investigators added that the drug also hit on a slate of secondary endpoints including progress-free survival, the objective response rate, and time to progression.
Eisai partnered with the powerhouse marketing team of Novartis in the US last summer, looking to co-promote this drug, which is already approved for treating kidney cancer in combination with Afinitor. The ongoing development plan of the company includes studies for biliary tract cancer and in combination with pembrolizumab for various types of cancer. Moreover, Eisai has launched a Phase III clinical study of lenvatinib in combinations with both everolimus and pembrolizumab in renal cell carcinoma for first-line use.